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ABSTRACT
Background We conducted a placebo-controlled trial
of azithromycin therapy in bronchiolitis obliterans
syndrome (BOS) post lung transplantation.
Methods We compared azithromycin (250 mg
alternate days, 12 weeks) with placebo. Primary outcome
was FEV1 change at 12 weeks.
Results 48 patients were randomised; (25
azithromycin, 23 placebo). It was established, post
randomisation that two did not have BOS. 46 patients
were analysed as intention to treat (ITT) with 33
‘Completers’. ITT analysis included placebo patients
treated with open-label azithromycin after study
withdrawal.
Outcome The ITT analysis (n=46, 177 observations)
estimated mean difference in FEV1 between treatments
(azithromycin minus placebo) was 0.035 L, with a 95%
CI of −0.112 L to 0.182 L (p=0.6). Five withdrawals,
who were identified at the end of the study as having
been randomised to placebo (four with rapid loss in
FEV1, one withdrawn consent) had received rescue open-
label azithromycin, with improvement in subsequent
FEV1 at 12 weeks. Study Completers showed an
estimated mean difference in FEV1 between treatment
groups (azithromycin minus placebo) of 0.278 L, with
95% CI for the mean difference: 0.170 L to 0.386 L
(p=<0.001). Nine of 23 ITT patients in the azithromycin
group had ≥10% gain in FEV1 from baseline. No patients
in the placebo group had ≥10% gain in FEV1 from
baseline while on placebo (p=0.002). Seven serious
adverse events, three azithromycin, four in the placebo
group, were deemed unrelated to study medication.
Conclusions Azithromycin therapy improves FEV1 in
patients with BOS and appears superior to placebo. This
study strengthens evidence for clinical practice of initiating
azithromycin therapy in BOS.
Trial registration number EU-CTR, 2006-000485-
36/GB.
INTRODUCTION
Lung transplantation can be the only life-sustaining
intervention for end-stage lung disease.1 Good
functional outcomes have been shown, with
improved quality of life.2 Long-term survival
remains limited by the development of the bron-
chiolitis obliterans syndrome (BOS) however.3
The histological lesion of BOS is obliterative
bronchiolitis. This is characterised by epithelial
alloimmune and non-alloimmune injury.4 5
Deterioration in allograft function is characterised
by the development of progressive, small airway
narrowing, fixed airflow limitation, progressive dys-
pnoea and premature death.6 International data
shows in excess of 50% of patients surviving to
5 years after transplantation develop BOS,6 limiting
10-year survival to around 30%.7
Therapeutic approaches have ranged from
switching immunosuppression6 through to initiat-
ing cytolytic therapy. Such approaches, including
the use of total lymphoid irradiation8 have, at best,
reduced the rate of decline in graft function in
BOS, with significant iatrogenic potential.8
In contrast, retrospective studies of macrolides, in
particular low dose azithromycin, have indicated
that up to 30% patients with BOS may gain lung
function. A number of international centres have
reported a clinical response to azithromycin therapy
in around a third of patients,9–13 with better life
expectancy.13 There have been negative studies,
however, with no gain in lung function.14–16 The
need for randomised controlled trial data has been
highlighted,17 but these have not been performed.
We tested the hypothesis that azithromycin
therapy is superior to placebo in patients with BOS
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Key messages
What is the key question?
▸ A number of international centres have
reported a clinically significant response to
azithromycin therapy in open studies of lung
transplant recipients with bronchiolitis
obliterans syndrome (BOS) but there are also
negative studies, where azithromycin therapy
was not associated with gain in lung function.
What is the bottom line?
▸ With no randomised placebo controlled studies
performed or published there was a clear
unmet need, met by this trial, which showed
on average that azithromycin was superior to
placebo treatment in our study population.
Why read on?
▸ This study outlines strengthened evidence for
the clinical practice of initiating azithromycin
therapy for patients who develop BOS post
lung transplantation.
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in a randomised double blind placebo controlled study. Some
results have been presented as abstracts.18 19
METHODS
Study design
Randomisation and masking
This was a single-centre randomised double-blind placebo-
controlled parallel group study comparing azithromycin
(250 mg on alternate days) with placebo over 12 weeks in lung
transplant recipients with BOS, with study drug taken in add-
ition to existing medication. Patients were randomly assigned to
a treatment arm in a 1:1 ratio using random permuted blocks
within strata. Study medication was provided by Bilcare, (Bilcare
GCS Europe, Powys, UK) a commercial clinical trial supplier,
independent of the manufacturers of azithromycin.
Patient population
Patients were recruited between November 2006 and December
2010 from the Freeman Hospital.
Withdrawal of patients from study
Patients who had a rapid and severe deterioration in lung function
were withdrawn from the study (for patient details see online
supplementary appendix 2). This was defined a priori as a sus-
tained 500 mL fall in FEV1 from baseline, before the full 12-week
course of study treatment, thought to be due to BOS. Patients
could also be withdrawn based on the clinical judgement of the
responsible clinician. Following withdrawal patients were treated
according to the usual centre and international practice, which
included the use of open-label azithromycin. The randomised
treatment allocation of withdrawn patients remained concealed.
Assessments
Spirometry
FEV1 and FVC were measured at baseline, week 4, week 8 and
week 12 in the Freeman Hospital.
Bronchoscopy, bronchoalveolar lavage and transbronchial biopsy
Patients underwent bronchoscopy at baseline (prerandomisa-
tion) and at final visit (week 12) as previously described.20
Transbronchial biopsies were taken at each allograft bronchos-
copy, fixed in 10% formalin, embedded in paraffin, and then
stained with haematoxylin and eosin (H&E) to assess acute vas-
cular and airway inflammation according to standard ISHLT cri-
teria by a pathologist.21
Outcome measures
The primary outcome measure was change in FEV1 from base-
line to 12 weeks. Secondary outcome measures reported here
are change in FVC from baseline and change in bronchoalveolar
lavage (BAL) neutrophils.
Study oversight
Newcastle University Clinical Trials Unit monitored the study.
An independent data monitoring committee was established to
assess accumulating recruitment, safety and efficacy data and to
oversee the trial conduct (Statistician (chair) and two consultant
respiratory physicians).
Sample size
Estimates of SDs of differences in FEV1 from baseline to
12 weeks in patients with lung transplant with BOS were based
on the Freeman Hospital data.41 A sample size of 64 patients,
32 patients per randomised group, allowed for 10% data
attrition. A recruitment period of 30 months was estimated to
be adequate to recruit 64 patients.
Statistical methods
The mean difference in FEV1 between treatment groups was
estimated using a multilevel random effects model assuming a
normal error structure within and between patients.22 The
models were fitted in MLwiN software (V.2.28).23 Random
effects models allow appropriate estimation of the treatment
effect (and associated SE) taking into account varying numbers
of measurements within patients and varying time between mea-
surements. Models were also adjusted for baseline FEV1 and the
two randomisation stratification variables.24 Model assumptions
were checked and analyses omitting possible outliers or influen-
tial observations were performed. The secondary outcome
measure, FVC, was analysed in the same way.
BAL neutrophil counts and their change from baseline to
12 weeks were summarised and presented as median and IQR.
The intention-to-treat population (ITT) was defined as all rando-
mised patients with BOS who received at least one dose of study
drug. The per protocol population was defined as all randomised
patients with BOS who followed the protocol and completed
12 weeks of study drug. Completers included all randomised
patients with BOS who completed 12 weeks of study drug.
An ‘as treated’ analysis was also performed; this was a ‘post
hoc’ analysis which had not been described in the statistical ana-
lysis plan and as such should be interpreted cautiously. Patients
who withdrew or were withdrawn from study drug were treated
with open-label azithromycin. The ‘as treated’ analysis provided
an estimate of the treatment effect allowing for treatment to
change over time. In this way a patient’s measurement contribu-
ted to the treatment effect based on the treatment they were
receiving at the time the measurement was taken and not the
treatment as randomised (for extended details see online
supplementary appendix 1).
RESULTS
Study patients
The CONSORT flow chart25 is presented in figure 1. Patient
withdrawals are detailed in the online supplementary appendix
2 (for extended details see online supplementary appendix 1).
All 46 patients in the ITT analysis set had baseline and final
visit FEV1 measured. Across all visits there were 177 FEV1 mea-
surements: 2 patients had 5 FEV1 measurements, 36 patients
had 4, 7 patients had 3, and 1 patient had 2 measurements.
There were 33 patients in the Completers analysis set (16 azi-
thromycin, 17 placebo). For the Completers analysis there were
124 FEV1 measures; 26 patients with 4 measurements, 6 patients
with 3 and 1 patient with 2 measurements.
The ‘as treated’ analysis used data on all 46 ITT patients and
all their 177 FEV1 measurements. For the five placebo patients
who were withdrawn and placed on open label azithromycin,
their measurements post withdrawal (nine measurements in
total across the five patients) contributed to the overall azithro-
mycin treatment mean and not the placebo treatment mean.
Baseline characteristics of the study patients, for the ITT and
Completer analysis sets, are summarised in table 1. All patients
initially received standard immunosuppressant comprising
ciclosporin, prednisolone and azathioprine. Patients with more
than one episode of vascular rejection requiring augmented ster-
oids in the 1st year post transplant and women with problematic
hirsute were switched to tacrolimus treatment. In the ITT popu-
lation 38 of 46 had switched to tacrolimus by enrolment; 18 in
the azithromycin group and 20 in the placebo group. All
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switches were in the 1st year post transplant, well before study
enrolment. All patients received proton pump inhibitors and
statin therapy, throughout the study. There were no relevant dif-
ferences in background immunosuppressant or other therapies
between the two groups. Results of lavage microbiology did not
lead to any change in baseline therapy and no patient enrolled
was regarded as having a new infection.
Analysis of FEV1 data
Figure 2A summarises FEV1 measurements as a two-panel spa-
ghetti plot of FEV1 over time in the study. Figure 2B sum-
marises FEV1 measurements in patients who were randomised
to the placebo arm and withdrew or were withdrawn and then
received open-label azithromycin. Results are summarised in
table 2. For the ITT analysis (n=46, 177 observations), the esti-
mated mean difference in FEV1 between treatment groups (azi-
thromycin minus placebo) was 0.035 L, (on average higher in the
azithromycin group) with a 95% CI for the mean difference of
−0.112 L to 0.182 L (p=0.6). Nine out of 23 (39%) ITT
patients in the azithromycin group had ≥10% gain in FEV1 from
baseline. No patients in the placebo arm had ≥10% gain in FEV1
from baseline while on placebo (p<0.002, Fisher’s exact test).
For the ‘as treated’ analysis (n=46, 177 observations) the esti-
mated mean difference in FEV1 between treatment groups
Figure 1 CONSORT flow chart25 summarising the progress of patients through the trial. BOS, bronchiolitis obliterans syndrome; ITT,
intention-to-treat.
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(azithromycin minus placebo) was 0.306 L, with 95% CI for the
mean difference: 0.181 L to 0.431 L (p=<0.001).
For study Completers the estimated mean difference in FEV1
between treatment groups (azithromycin minus placebo) was
0.278 mL, with 95% CI for the mean difference: 0.170 L to
0.386 L (p=<0.001).
Analysis of FVC data
The results are summarised in table 3. For the ITT population,
(n=46, 177 observations), the estimated mean difference in
FVC between treatment groups (azithromycin minus placebo)
was 0.099 L, with 95% CI for the mean difference: −0.026 L to
0.224 L (p=0.1).
For the ‘as treated’ analysis (n=46, 177 observations)
the estimated mean difference in FVC between treatment
groups (azithromycin minus placebo) was 0.272 L, with
95% CI for the mean difference: 0.158 L to 0.386 L
(p=<0.001).
For study Completers, the estimated mean difference in FVC
between treatment arms (azithromycin minus placebo) was
0.248 L, with 95% CI for the mean difference: 0.115 L to
0.381 L (p=<0.001).
BAL neutrophil data
BAL data was not available from all patients due to a clinical
decision that the sample was either not possible or prudent
Table 1 Baseline characteristics for the intention-to-treat (ITT, n=46) and Completer (Comp, n=33) populations, by treatment allocation group
Baseline characteristic ITT azithromycin n=23 ITT placebo n=23 Comp azithromycin n=16 Comp placebo n=17
Sex
Female 12 (52%) 8 (35%) 9 (56%) 7 (41%)
Male 11 (48%) 15 (65%) 7 (44%) 10 (59%)
Age (years), median (IQR) 51.0 (35–56) 51.0 (44–59) 53.5 (47.0–57.5) 54.0 (45.0–62.0)
Pretransplant (Tx) disease
Cystic fibrosis 7 (30%) 6 (26%) 2 (13%) 4 (24%)
Emphysema 11 (48%) 8 (35%) 9 (56%) 6 (35%)
Fibrosing alveolitis 2 (9%) 4 (17%) 2 (13%) 3 (18%)
Other* 3 (13%) 5 (22%) 3 (19%) 4 (24%)
Tx procedure
Double lung 14 (61%) 13 (57%) 7 (44%) 9 (53%)
Single lung 9 (39%) 9 (39%) 9 (56%) 7 (41%)
Heart lung 0 1 (4%) 0 1 (6%)
Years between Tx and BOS
Median (IQR) 3.7 (1.3–7.4) 2.2 (1.3–5.0)† 4.2 (2.6–7.8) 2.0 (1.3–4.0)
BOS stage
1 13 (57%) 17 (74%) 10 (63%) 13 (77%)
2 8 (35%) 4 (17%) 6 (38%) 3 (18%)
3 2 (9%) 2 (9%) 0 1 (6%)
FEV1 (litres), median (IQR) 1.5 (1.2–2.4) 1.7 (1.5–2.5) 1.6 (1.2–2.4) 1.7 (1.5–2.2)
FVC (L), median (IQR) 3.0 (2.3–3.6) 2.9 (2.2–3.6) 2.7 (2.1–3.6) 2.9 (2.1–3.5)
TBB A and B scores‡
Missing 2 (9%) 4 (17%) 2 (13%) 3 (18%)
Ax 5 (22%) 8 (35%) 3 (19%) 7 (41%)
A0 12 (52%) 7 (30%) 7 (44%) 4 (24%)
A1 4 (17%) 3 (13%) 4 (25%) 2 (12%)
A2 0 1 (4%) 0 1 (6%)
Missing 2 (9%) 4 (17%) 2 (13%) 3 (18%)
Bx 5 (22%) 7 (30%) 5 (31%) 4 (24%)
B0 5 (22%) 6 (26%) 2 (13%) 5 (29%)
B1R 9 (39%) 6 (26%) 7 (44%) 5 (29%)
B2R 2 (9%) 0 0 0
BAL microbiology
Missing 2 (9%) 2 (9%) 2 (13%) 1 (6%)
NPI 11 (48%) 14 (61%) 8 (50%) 11 (65%)
‘Any’ organism 10 (43%) 7 (30%) 6 (38%) 5 (29%)
‘Any’ includes: Pa 5 4 3 3
Asp Fum 2 0 1 0
Ca 4 2 2 1
Other 2 1 1 1
*Other Pre Tx disease: Obliterative Bronchiolitis, Sarcoid, Congenital heart disease, Histiocytosis X, Silicosis.
†One patient randomised to the placebo arm >10 years post transplant (at 11.9 years).
‡ISHLT grades (ref 20) BAL Microbiology=Clinical microbiology. Other=Proteus mirabilis, Stenotrophomonas Maltophilia, Ralstonia Picketti, Candida species. Percentages for patients
growing individual organisms are not given since some patients grew more than one organism.
Asp Fum, Aspergillus fumigatus; BAL, bronchoalveolar lavage; BOS, bronchiolitis obliterans syndrome; Ca, Candida albicans; NPI, no pathogens identified; Pa, Pseudomanas aeruginosa;
TBB, transbronchial biopsy.
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because of the clinical status of the patients during the
bronchoscopy.
At baseline BAL differential data were available for 39/46
(85%) of the ITT analysis set. The median per cent neutrophils
in BAL was 25.8% (IQR 3.4–72.0%).
BAL neutrophil data were available at baseline and final
visit for 28/46 patients in the ITT analysis set (13/23 azi-
thromycin, 15/23 placebo) and 25/33 in the Completers
analysis set (12/16 azithromycin, 13/17 placebo). Summary
statistics for baseline, final and change in BAL neutrophil
percentage are given in table 4. There was no evidence of
systematic changes in BAL neutrophil percentage associated
with either azithromycin or placebo treatment for either
the ITT (figure 3A) or study Completer populations
(figure 3B).
Transbronchial biopsy data
Where paired data were available approximately half of the
biopsies were graded as ‘Bx’ (ungradeable) for the B scores and
a third were ‘Ax’ (ungradeable) for the A scores. Further analysis
of the potential effect of azithromycin on biopsy scores was
therefore not carried out. The data is summarised in online sup-
plementary appendix 3.
Safety
Seven adverse events led to hospital admission or the prolong-
ing of existing hospitalisation. They were therefore classified as
serious, but not related to study medication. There were no
other major safety issues to report with the trial.
DISCUSSION
To our knowledge this is the first randomised controlled study
of azithromycin therapy in BOS. Our trial showed that azithro-
mycin improves FEV1 and FVC in a significant proportion of
patients. As in previous open studies not all patients with BOS
responded to azithromycin.
We also noted that in patients treated with placebo who were
withdrawn from the study due to rapid fall in lung function,
treatment with open label azithromycin was associated with a
significant gain in lung function leading to our decision to
report our Completers and ‘as treated’ groups. We recognise
that our ‘as treated’ analysis should be interpreted cautiously, as
a post hoc analysis. Overall we conclude that azithromycin
appears superior to placebo treatment in our study.
An implication of the present study is that the definition of
BOS, which currently includes the presence of irreversible
Figure 2 (A) FEV1 measurements as a two-panel spaghetti plot of FEV1 over time in the study. The thickened lines denote FEV1 from the time a
patient withdrew or was withdrawn from study medication. FEV1.0 versus days (placebo group; solid squares) and FEV1.0 versus days (azithromycin
group; solid circles). (B) Descriptive plot of FEV1 data for patients treated with placebo who withdrew or were withdrawn from study medication.
Symbols, different for each patient (key) denote FEV1 measurements. ID, anonymised patient identifier. ‘P’ indicates where a patient was being
treated with placebo at the time FEV1 was measured. ‘A’ denotes where a patient was being treated with azithromycin at the time FEV1 was
measured, after withdrawal from study. Patient 48 was withdrawn from study medication following stomach pains and did not receive azithromycin.
Patient 51 withdrew consent and was treated with open-label azithromycin. The remaining four patients had ‘rapid fall’ in FEV1 and were withdrawn
and treated with open label azithromycin.
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airflow obstruction, should be revised or a new term introduced
to describe a phenotype of patient who fulfils the definition of
BOS, apart from showing a response to azithromycin. This has
been suggested prominently by others.5
A limitation of our study was randomisation of 48 subjects
versus the target of 64. The incidence of BOS throughout the
potential trial population was below that estimated.
Consequently, our recruitment rate was on average one per
month rather than the estimated rate of two per month. Our
recruitment period ran for 48 months rather than the antici-
pated 30 months. This resulted in having data available from 46
patients for the ITT analysis compared with the target of 58.
This shortfall would be expected to reduce the power of the
study. However, the observed SD of the change in FEV1 from
baseline was also much smaller than anticipated at design, a
factor that would be expected to favour the study power. In line
with CONSORT guidelines,25 we reported 95% CIs for the
trial, allowing open interpretation of the findings to be consid-
ered along with study size.
Our study compliments a previous randomised trial in lung
transplantation where azithromycin was used as prophylaxis
against developing BOS. This had a primary end point of
freedom from BOS and survival 2 years after lung transplant-
ation.26 This found that BOS-free survival was better with azi-
thromycin. Patients receiving azithromycin had better FEV1,
and lower airway neutrophilia.26 When open-label azithromy-
cin was initiated in patients with BOS, this was associated
with an improvement of FEV1 in around half the patients
treated.26
Our study was powered to detect a change in FEV1. FEV1 is
the basis for the internationally recognised classification of BOS
and has previously been reported in open studies of azithromy-
cin therapy,9–13 and was reported in the sole previous rando-
mised trial of azithromycin for BOS prophylaxis.26FVC may be
sensitive to changes in the calibre of smaller, peripheral
airways.27 28 Our data indicated that azithromycin was superior
to placebo for FVC in the Completer population and ‘as
treated’ analysis.
Our current and previously reported data29 therefore suggest
that FVC and other tests such as FEF25–75% may be useful end
points for intervention studies in BOS. Previous open studies of
azithromycin therapy, including work from our own centre have
not reported FVC data9–13 or focused on physiological measure-
ments which reflect smaller airway function. It would seem rea-
sonable to report such measurements given the recognised small
airway contribution to BOS pathophysiology, and that the mea-
surements are readily made.
As a secondary end point we analysed the effects of azithro-
mycin therapy on BAL neutrophils, reflecting our long-standing
interest30 31 BOS has a neutrophilic pathophysiology and it has
been suggested that the clinical heterogeneity of BOS may be
clarified by considering a distinct patient subset with neutro-
philic reversible allograft dysfunction.5 This proposed dichot-
omy may have important therapeutic implications in predicting
patients who might respond to azithromycin.5 In a significant
number of our patients no BAL data were available. The
samples that were available confirmed our previous finding,30
and others’32 33 that BOS is accompanied by an elevated BAL
Table 2 Mean difference in FEV1 between treatment groups for the intention-to-treat (ITT, n=46), ‘as treated’ (n=46) and Completer (n=33)
populations
Outcome FEV1 (L)
Mean difference in FEV1
(azithromycin minus placebo)
95% CI for population
mean difference p Value
ITT analysis 46 patients, 177 measurements
Mean difference in FEV1 between treatment arms, adjusted for baseline FEV1,
randomisation stratification variables (disease and transplant)
and time since randomisation
0.035 −0.112 to 0.182 0.6
‘As treated’ analysis 46 patients, 177 measurements
Mean difference in FEV1 between treatment arms, adjusted for baseline FEV1,
randomisation stratification variables (disease and transplant) and time since randomisation
0.306 0.181 to 0.431 <0.001
Completers analysis 33 patients, 124 measurements
Mean difference in FEV1 between treatment arms, adjusted for baseline FEV1,
randomisation stratification variables (disease and transplant) and time since randomisation
0.278 0.170 to 0.386 <0.001
Table 3 Mean difference in FVC between treatment groups for the intention-to-treat (ITT, n=46), ‘as treated’ (n=46) and Completer (n=33)
populations
Outcome FVC (L)
Mean difference in FVC
(azithromycin minus placebo)
95% CI for population
mean difference p Value
ITT analysis 46 patients, 177 measurements
Mean difference in FVC between treatment arms, adjusted for baseline FVC, randomisation
stratification variables (disease and transplant) and time since randomisation
0.099 −0.026 to 0.224 0.1
‘As treated’ analysis 46 patients, 177 measurements
Mean difference in FVC between treatment arms, adjusted for baseline FVC, randomisation
stratification variables (disease and transplant) and time since randomisation
0.272 0.158 to 0.386 <0.001
Completers analysis 33 patients, 124 measurements
Mean difference in FVC between treatment arms, adjusted for baseline FVC, randomisation
stratification variables (disease and transplant) and time since randomisation
0.248 0.115 to 0.381 <0.001
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neutrophil count. However azithromycin therapy was not asso-
ciated with a change in neutrophils. Our findings are therefore
different to the Leuven Centre which has published data indicat-
ing that a fall in neutrophilic inflammation occurs in patients
with a clinical response to azithromycin. We feel that the limited
data available for analysis in our study precludes firm conclu-
sions being drawn. We would therefore recommend that further
research is performed to clarify the relationship between BAL
neutrophil levels and the clinical effectiveness of azithromycin
treatment.
Apart from potential anti-inflammatory benefits, which may
include effects on neutrophil numbers and function, other
effects of macrolide therapy have been reviewed elsewhere and
warrant further study. These include immunomodulatory
mechanisms, interference in the formation of infective biofilms
and alleviation of extraoesophageal reflux and microaspiration,
with promotion of gastric motility.34 It is increasingly recognised
that reflux and aspiration may be an important injury in lung
allografts,35 and we would recommend that characterisation of
reflux disease is considered in future intervention trials in BOS.
In our study azithromycin treatment was not associated with
significant adverse events. There were no deaths or graft losses
during the study. It has been suggested that prolonged treatment
with azithromycin may have adverse effects which may be of
potential relevance in lung transplantation. These include
gastrointestinal effects, loss of hearing36 and the development of
macrolide resistant organisms.34 It is also suggested that azithro-
mycin could predispose patients to the development of non-TB
Table 4 Per cent neutrophils in bronchoalveolar lavage at baseline and final visit (week 12) for the intention-to-treat (ITT) (n=28/46) and
Completer (n=25/33) populations, by treatment allocation
n
Baseline
Median (IQR)
Final visit
Median (IQR)
Change from baseline
Median (IQR)
ITT azithromycin 13/23 16.6 (4.2 to 68.8) 32.0 (10.0 to 69.5) 9.8 (−10.4 to 17.7)
ITT placebo 15/23 14.8 (2.4 to 56.0) 19.8 (2.0 to 52.2) −0.5 (−7.8 to 5.0)
Completers azithromycin 12/16 16.1 (3.7 to 61.5) 31.5 (7.5 to 73.3) 11.9 (−7.7 to 18.9)
Completers placebo 13/17 9.2 (2.0 to 52.5) 19.8 (1.5 to 46.9) −0.5 (−7.5 to 4.9)
Figure 3 (A) The change in per cent neutrophils in bronchoalveolar lavage (BAL) from baseline to week 12 for the intention-to-treat (ITT)
population, by treatment allocation group (n=28/46). Median change denoted by horizontal line. (B) The change in per cent neutrophils in BAL from
baseline to week 12 for the Completer population, by treatment allocation group (n=25/33). Median change denoted by horizontal line. (C) The
change in per cent neutrophils in baseline to week 12 for patients treated with azithromycin who had <10% gain in FEV1 (solid circles) and in
patients treated with azithromycin who had a >10% gain in FEV1 (solid squares).
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mycobacterial infection.37 Debate has also been generated by a
study of azithromycin use in a group of patients with pre-
existing heart disease. Here azithromycin treatment was asso-
ciated with an increased rate of cardiovascular related mortal-
ity.38 It has also been shown that the macrolide antibiotics may
cause cholestatic hepatitis at an estimated rate of 3.6 per
100 000.39
While azithromycin treatment in BOS is generally safe, and
provides a therapeutic opportunity in a pathophysiology causing
significant morbidity and mortality,9 10 12–16 26 40 it remains a
research priority to elucidate which patients benefit from azi-
thromycin, what the optimum timing of treatment is and to
provide long-term follow-up data. This might lessen the possi-
bility of iatrogenic consequences of therapy, although these are
also the subject of investigation and debate, with the possibility
that risks have been overestimated generally, and may not be
especially relevant in the specialised setting of lung transplant-
ation. We consider the potential benefits of alternate day low
dose azithromycin 250 mg outweigh the potential risks in lung
transplantation. Ideally the results of this trial should be
replicated.
We conclude that this study provides strengthened evidence
for the clinical practice of initiating azithromycin therapy for
patients who develop BOS post lung transplantation.
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